LEON NANODRUGS - Key Persons
Christian brings a wealth of experience and expertise in the management of successful businesses.
Having held board-level positions including CEO and CFO at global companies for more than 25 years, Christian is equipped with a wealth of senior experience in business management and finance. With a focus on life sciences, he has successfully led the delivery of several M&A's, financing rounds as well as license contracts and supply agreements.
Frank has held leadership positions across the pharmaceutical and biotech industry for more than 25 years.
He is currently Chief Executive Officer of Rentschler Biopharma SE and also Chairman of vfa bio, which represents the biotech interests within the German Association of Research-Based Pharmaceutical Companies.
From 2009 until 2016, Frank was Chief Executive Officer of Medigene AG, having joined the company in 2008 as Chief Operating Officer.
Prior to that he worked for Amgen GmbH, Servier Deutschland and Hoechst AG.
He is a graduate of Paris VI University, where he studied immunology.
Job Titles:
- CHIEF SCIENTIFIC & INNOVATION OFFICER
Frank is a Qualified Person (QP) and a leading authority in pharmaceutics, biotechnology and validation of aseptic processes. He has Co-founded a number of companies IFAP AG, GEFAP GmbH and Aukamm Pharma GmbH and lectured in pharmaceutical technology at the University of Frankfurt. As author of one of the first nano particle patents, facilitating one of the first bioprocessing technical transfers and performing one of the first QP releases of a gene transfer IMP, Frank brings more than 30 years of experience within the pharmaceutical industry, life science sectors and academic.
Gerhard has more than 20 years' experience in global life sciences and venture capital, both as an entrepreneur and investor.
Hubert is responsible for overall investment strategy and global fund operations at TVM Capital Life Science, and holds a number of chairmanships in leading life sciences companies.
Prior to his current role, he was Head of Business Development Europe and Director of Marketing for Germany at Zeneca Agrochemicals, having joined from McKinsey & Company's European healthcare and pharmaceutical practice. As a management consultant, he gained extensive experience in R&D management, marketing and sales, and joint venture structuring and business development. Hubert holds a doctoral degree in biochemistry and has an MBA from Harvard Business School.
Paul brings more than 25 years of business development and senior management experience in the pharmaceutical and health care industries. As a proactive business development (BD) professional with considerable international knowledge, he has led BD and sales teams in the US, EU, UK and Japan. Furthermore, he has gained a wealth of contracting and alliance management experience. Paul is an immunologist by training, holds a management qualification from London Business School and has served on several Boards of start-up companies.
Peter has extensive experience in the IT sector, having founded a Munich- and Berlin-based IT company and delivered successful software projects for clients such as BMW, Diebel's and Hypovereinsbank. During his time at the Max Planck Institute of Biochemistry, Peter worked on the mechanisms of cell cycle regulation, generating and analysing whole genome data of protein-binding sites and gene-expression data using a combination of wet lab and bioinformatic methods. He holds an degree in Agricultural Sciences and Molecular Biology (with high distinction) and obtained his PhD from LMU Munich.
Robert has more than 35 years of experience in the pharmaceutical industry. Earlier in his career, he held various leadership positions at Boehringer-Ingelheim, Eli Lilly and Company Biogen Idec and Aptalis.
In 2014 he founded Impala Pharma Consulting supporting academic and NGO institutions, Start-up companies, Pharma and Biotech companies from idea generation to launch. He has a strong background in pharmaceutical product development, established a broad vendor network for API, DP and analytical methods development and created strategic partnerships with major collaboration partners for small molecule and protein formulation development. Robert is an expert in process chemistry, design and development of formulations across all pharmaceutical dosage forms and drug delivery systems. Robert is a Chemist by training with focus on Physical Chemistry and holds his Ph.D. from the Technical University Munich, Germany.
Job Titles:
- Chief Financial Officer
- MEMBER of the BOARD
Enno is Chief Financial Officer and a member of the Management Board of Evotec.
He previously held the roles of Chairman, CEO and CFO of 4SC AG, having joined the company in September 2005 in the capacity of CEO. Before working for 4SC, Enno was Head of Finance and Controlling at BioM AG, a German regional biotech venture fund, where his responsibilities included finance and controlling as well as managing investments in the equity portfolio. He held the position of Interim Managing Director at two portfolio companies - ACTIPAC Biosystems GmbH and Munich Innovative Biomaterials GmbH - and in 2001, took on the role of Management Partner of BioM VC Fund. Enno earned his Masters in Business from the University of Bamberg, Germany.
Job Titles:
- STRATEGIC INDUSTRY ADVISOR
Massimo has a wealth of experience from over 25 years in the pharmaceutical sector in senior industrial roles and at the interface between research and commercial application of innovative solutions. Holding an MBA in Business Management, he has acquired multidisciplinary expertise in pharmaceutical development and drug delivery technologies, as well as in the regulatory landscape. In addition, Massimo has lead optimization insights across all preclinical and clinical phases.